α-defensin 1-3 and α-defensin 4 as predictive markers of imatinib resistance and relapse in CML patients.
Résumé
Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukaemia. Despite a remarkable effectiveness, treatment failure cases have been reported in 20 percent of CML patients. The identification of biomarkers which can predict the response to imatinib is our point of interest.
Domaines
Cancer
Origine : Fichiers éditeurs autorisés sur une archive ouverte